Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Best Pract Res Clin Haematol. 2013 Mar;26(1):33-41. doi: 10.1016/j.beha.2013.04.004. Epub 2013 May 23.
In children, T and NK-cell lymphomas are uncommon in Western Countries. While there has been significant experience treating T-cell lymphoblastic lymphoma (T-LBL) and anaplastic large cell lymphoma (ALCL), other subtypes are very rarely encountered and there are no standard approaches to their management. There are many challenges in defining optimal therapy for many of these diseases but recent progress in elucidating their biology has led to new molecular insights and identified interesting targets for novel drug discovery. In this review, we discuss these disorders in children, how they are approached therapeutically and what lies on the horizon with respect to novel treatment approaches.
在西方国家,儿童 T 细胞和 NK 细胞淋巴瘤并不常见。虽然在治疗 T 细胞淋巴母细胞淋巴瘤(T-LBL)和间变性大细胞淋巴瘤(ALCL)方面已有丰富经验,但其他亚型非常罕见,其治疗方法也尚无标准。许多此类疾病的最佳治疗方法的定义都面临着诸多挑战,但最近在阐明其生物学特性方面的进展为新型药物发现提供了新的分子见解和有前景的靶点。在这篇综述中,我们讨论了儿童中的这些疾病,它们的治疗方法以及新型治疗方法的前景。